Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
← catalyst calendarSponsored by ADC Therapeutics S.A. (industry) · ADCT — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
440actual
Sites
144
Countries
Argentina, Belgium, Brazil +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-16 | actual | When the study began enrolling |
| Primary completion | 2026-03-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2020-05-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
Interventions
- Drug: Loncastuximab Tesirine — also filed as Zynlonta, ADCT-402
- Drug: Rituximab
- Drug: Gemcitabine
- Drug: Oxaliplatin
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS)
measured Up to 4 years
Permalink · ADCT's whole pipeline · Catalyst calendar · Every registered study · What changed